Company news
Hikma Pharmaceuticals Plc (LSE:HIK) news
Hikma Pharmaceuticals Plc news releases on 6ix. Latest, Jan 29, 2019: Hikma launches Mitomycin for Injection
Press releases — page 3
Hikma launches Mitomycin for Injection
January 29, 2019
Hikma announces agreement with Sciecure Pharma
January 3, 2019
Hikma launches Clobazam
December 10, 2018
Hikma announces injectable licensing agreement
November 27, 2018
Hikma launches Triazolam Tablets
November 19, 2018
Hikma announces agreement with Vectura
November 8, 2018
Hikma enters licensing partnership with Perrigo
July 9, 2018
Hikma appoints Chief Transformation Officer
June 4, 2018
Hikma launches Methylergonovine Maleate Tablets
May 30, 2018
AGM Results
May 18, 2018
Hikma launches Methotrexate Injection
May 3, 2018
Hikma expands licensing agreement with Rovi
April 24, 2018
Hikma launches Dexrazoxane for Injection
April 20, 2018
Hikma launch-Palonosetron Hydrochloride Injection
March 29, 2018
Hikma has launched Ritonavir Tablets USP
March 20, 2018
Update status on ANDA for generic Advair Diskus®
March 12, 2018
Sigurdur Olafsson appointed CEO of Hikma
February 20, 2018
Hikma Appoints Dr. Surendera Tyagi
January 15, 2018
Hikma reaches licensing agreement with Celltrion
December 19, 2017
Hikma- Dihydroergotamine Mesylate Injection, USP
December 13, 2017
Hikma Ventures- $20.5m Series C round for Prognos
November 30, 2017
Announcement
November 28, 2017
Hikma Ventures invests in Biolinq
November 27, 2017
Hikma Acquires Products from Boehringer Ingelheim
November 14, 2017
Hikma launches Flucytosine Capsules USP in US
November 3, 2017
Hikma launches Pantoprazole Sodium for Injection
October 30, 2017
Hikma announces licensing agreement with Takeda
August 17, 2017
Leadership and Structural Changes to US Business
June 26, 2017
Hikma update on ANDA for generic Advair Diskus
May 11, 2017
Change of Registered Address
May 8, 2017
Change of Registered Office
May 3, 2017
Hikma enters into settlement agreement with Jazz
April 6, 2017
Hikma launches Desvenlafaxine Succinate Tablets
March 10, 2017
Licensing agreement with Orion for Easyhaler®
February 13, 2017
Hikma receives approval for Sodium Oxybate
January 18, 2017
Board appointment and succession
September 20, 2016
Regulatory approval of Hikma's colchicine upheld
July 21, 2016
Launch of Generic Xeloda® Tablets in the US
July 20, 2016
Further re Colchicine Litigation
May 19, 2016
AGM Statement
May 12, 2016
Doc re. Bond Guarantor Group
May 6, 2016
Update on ANDA for Generic Advair Diskus®
April 8, 2016
Annual Information Update
April 7, 2016
Blocklisting Interim Review
April 6, 2016
Roxane Acquisition Close
February 29, 2016
EGM Statement
February 19, 2016
Circ re. Roxane Acquisition
February 11, 2016
Hikma Analyst and Investor Call
February 10, 2016
Circ re. Roxane Acquisition and EGM
January 22, 2016
Shareholders' Agreement and Board Appointment
December 24, 2015